Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

PURPOSE: The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide–paclitaxel regimen. PATIENTS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Vaz-Luis, Ines, Barroso-Sousa, Romualdo, Di Meglio, Antonio, Hu, Jiani, Rees, Rebecca, Sinclair, Natalie, Milisits, Lindsey, Leone, Jose Pablo, Constantine, Michael, Faggen, Meredith, Briccetti, Frederick, Block, Caroline, O'Neil, Kelly, Partridge, Ann, Burstein, Harold, Waks, Adrienne G., Trippa, Lorenzo, Tolaney, Sara M., Hassett, Michael, Winer, Eric P., Lin, Nancy U.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367545/
https://ncbi.nlm.nih.gov/pubmed/32330102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02484
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados